{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000055","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.023564+00:00","generated_at":"2026-06-22T21:00:51.239663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurocrine Q3 2022: INGREZZA sales $376M, GAAP EPS $0.69; raises FY guidance","bullets":["Q3 INGREZZA net product sales $376M (+31% YoY); TRx ~68,600 (+32% YoY).","GAAP net income $68.5M ($0.69 diluted EPS); non-GAAP net income $106.7M ($1.08 EPS).","Total revenue $387.9M, up 31% from $296.0M in Q3 2021.","Raised 2022 INGREZZA sales guidance to $1.400-$1.425B; R&D & SG&A guidance reaffirmed.","Acquired Diurnal Group plc for ~£48.3M (~$56M); sNDA for valbenazine in Huntington chorea submitted."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000055","json":"https://secwatch.observer/filing/0000914475-22-000055.json","markdown":"https://secwatch.observer/filing/0000914475-22-000055.md","text":"https://secwatch.observer/filing/0000914475-22-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/nbix-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:00:51.239663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23eb100f3d00160854cd3c2e8c41fe8d00a750c9","claim":"NEUROCRINE BIOSCIENCES INC reported Third quarter ended September 30, 2022 results: revenue Total revenues $ 387.9, net income GAAP net income $ 68.5, EPS GAAP earnings per share – diluted $ 0.69.","evidence_excerpt":"Total revenues $ 387.9 $ 296.0 $ 1,076.7 $ 821.5 GAAP Research and Development (R&D) $ 107.7 $ 92.7 $ 345.8 $ 240.7 Non-GAAP R&D $ 92.8 $ 80.7 $ 302.2 $ 204.5 GAAP Selling, General and Administrative (SG&A) $ 186.3 $ 154.6 $ 569.8 $ 426.8 Non-GAAP SG&A $ 158.1 $ 129.5 $ 483.8 $ 364.4 GAAP net income $ 68.5 $ 22.5 $ 65.5 $ 96.9 GAAP earnings per share – diluted $ 0.69 $ 0.23 $ 0.67 $ 0.99","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third quarter ended September 30, 2022"},{"label":"Revenue","value":"Total revenues $ 387.9"},{"label":"Net income","value":"GAAP net income $ 68.5"},{"label":"EPS","value":"GAAP earnings per share – diluted $ 0.69"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5b0a82789b0b8aaebffbe1aabc5f21b165d59f87","claim":"NEUROCRINE BIOSCIENCES INC reported Fiscal year 2022 results: revenue INGREZZA Net Product Sales 1 $ 1,400 $ 1,425. Guidance raised.","evidence_excerpt":"Updated 2022 INGREZZA Sales and Reaffirmed Operating Expense Guidance: Range (in millions) Low High INGREZZA Net Product Sales 1 $ 1,400 $ 1,425 GAAP R&D expense 2 $ 415 $ 450 Non-GAAP R&D expense 3 $ 360 $ 395 GAAP SG&A expense $ 720 $ 735 Non-GAAP SG&A expense 3 $ 605 $ 620 1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fiscal year 2022"},{"label":"Revenue","value":"INGREZZA Net Product Sales 1 $ 1,400 $ 1,425"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}